Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RARG | P13631 | 11/20 | 1.00 |
| ▸ | RXRB | P28702 | 8/20 | 1.00 |
| ▸ | RXRG | P48443 | 8/20 | 1.00 |
| ▸ | RARA | P10276 | 7/20 | 1.00 |
| ▸ | RARB | P10826 | 7/20 | 1.00 |
| ▸ | PPARG | P37231 | 10/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502044 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL5175957 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL502045 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8899800 | 0.94 | RXRA (0.88) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL13752421 | 0.89 | RXRA (0.81) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8568634 | 0.89 | RXRA (0.80) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8568632 | 0.89 | RXRA (0.80) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL20646225 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6344906 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6344909 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025024484-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-20240285540-A1 | FUNCTIONAL THERAPEUTIC INDEX IN THE TREATMENT OF PERIPHERAL IMMUNE DYSFUNCTION | MASCARENHAS DESMOND (US) | 2024-08-29 | — | — | US | claimed |
| US-11951158-B2 | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-04-09 | — | — | US | claimed |
| EP-4334436-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Yeda Research and Development Co. Ltd (IL) | 2024-03-13 | — | — | EP | claimed |
| US-20240074473-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-07 | — | — | US | claimed |
| US-11642419-B2 | Compositions and methods for treating cardiovascular related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-05-09 | — | — | US | claimed |
| WO-2022234586-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-11-10 | — | — | WO | claimed |
| EP-1621191-A1 | Treatment of inflammatory diseases by RXR Antagonists | Bollag, Werner (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | RXRA 18/4885RARG 382/4885RXRB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.